Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 12, 2012

FDA clears Genentech Lucentis injection for DME treatment

The US Food and Drug Administration (FDA) has cleared Genentech's Lucentis 0.3mg (ranibizumab injection), a recombinant humanised monoclonal antibody fragment (lacking an Fc region) designed to treat diabetic macular edema (DME).

The US Food and Drug Administration (FDA) has cleared Genentech’s Lucentis 0.3mg (ranibizumab injection), a recombinant humanised monoclonal antibody fragment (lacking an Fc region) designed to treat diabetic macular edema (DME).

The approval of Lucentis in DME was based on Genentech’s parallel, double-masked, three-year Phase III RIDE and RISE trials, which were sham-treatment controlled for 24 months.

A total of 759 patients were randomised into three groups to receive monthly treatment with 0.3mg Lucentis (n=250), 0.5mg Lucentis (n=252) or sham injection (control group, n=257).

Lucentis 0.5mg once monthly was approved by the FDA for treatment of wet age-related macular degeneration (AMD) in 2006 and for macular edema following retinal vein occlusion (RVO) in 2010, according to the company.

The results demonstrated that patients who received 0.3mg Lucentis experienced significant, early (day seven) and sustained (24 months) improvements in vision.

A total of 759 patients were randomised into three groups to receive monthly treatment with 0.3mg Lucentis, 0.5mg Lucentis or sham injection.

Vision improvements observed in patients treated with Lucentis at 24 months were maintained with continued treatment through 36 months.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Pooled safety analysis of RIDE and RISE at 24 months showed that the ocular safety of Lucentis in patients with DME was generally consistent with that established in patients with wet AMD and RVO (through 36 months).

The rate of arteriothromboembolic events at 36 months was 10.8% for patients in the 0.3mg treatment group (control period ended at 24 months), while the rate of stroke in DME patients at 24 months was 1.2%, 0.3mg versus 1.6%, control. At 36 months the rate of stroke was 2% for this treatment group.

Genentech chief medical officer and global product development head Hal Barron said, "We developed Lucentis to treat diseases of the eye and are pleased to have received this third US indication to help a new population of people whose eyesight may be affected by diabetes."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU